Filing Flows › Caribou Biosciences (CRBU) › Q3 2026 › vs Q2 2026
Caribou Biosciences (CRBU) Q3 2026 vs Q2 2026 (quarter over quarter)
Caribou Biosciences's revenue rose $108K (+7%) from $1.5M in Q2 2026 to $1.6M in Q3 2026.
Caribou Biosciences, Q3 2026: revenue $1.6M (-27% year over year), net loss $26.6M, operating cash flow −$22.5M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.6M | $1.5M | $108K | +7% |
| Other income, net | $1.0M | $1.1M | −$27K | -3% |
| Net loss | $26.6M | $24.3M | $2.3M | +10% |
| Costs & expenses | $29.2M | $26.8M | $2.4M | +9% |
| Operating costs | $29.2M | $26.8M | $2.4M | +9% |
| Research & development | $21.3M | $18.9M | $2.4M | +13% |
| General & admin | $7.9M | $7.9M | $4K | +0.1% |
| Operating cash sources | $26.6M | $24.3M | $2.3M | +10% |
| Depreciation & amortization | $590K | $625K | −$35K | -6% |
| Share-based compensation | $2.2M | $2.5M | −$314K | -13% |
| Working capital & other | $1.3M | −$1.6M | $2.9M | — |
| Cash used in operations | $22.5M | $22.8M | −$269K | -1% |
| Net loss absorbed | $26.6M | $24.3M | $2.3M | +10% |
Questions
How much did Caribou Biosciences's revenue grow quarter over quarter in Q3 2026?
Caribou Biosciences's revenue rose $108K (+7%) from $1.5M in Q2 2026 to $1.6M in Q3 2026.